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CASE REPORT
Spectrum of digoxin-induced ocular 
toxicity: a case report and literature review
Delphine Renard1*, Eve Rubli2, Nathalie Voide3, François‑Xavier Borruat3 and Laura E. Rothuizen1
Abstract 
Background: Digoxin intoxication results in predominantly digestive, cardiac and neurological symptoms. This case 
is outstanding in that the intoxication occurred in a nonagenarian and induced severe, extensively documented 
visual symptoms as well as dysphagia and proprioceptive illusions. Moreover, it went undiagnosed for a whole month 
despite close medical follow‑up, illustrating the difficulty in recognizing drug‑induced effects in a polymorbid patient.
Case presentation: Digoxin 0.25 mg qd for atrial fibrillation was prescribed to a 91‑year‑old woman with an esti‑
mated creatinine clearance of 18 ml/min. Over the following 2–3 weeks she developed nausea, vomiting and dyspha‑
gia, snowy and blurry vision, photopsia, dyschromatopsia, aggravated pre‑existing formed visual hallucinations and 
proprioceptive illusions. She saw her family doctor twice and visited the eye clinic once until, 1 month after starting 
digoxin, she was admitted to the emergency room. Intoxication was confirmed by a serum digoxin level of 5.7 ng/ml 
(reference range 0.8–2 ng/ml). After stopping digoxin, general symptoms resolved in a few days, but visual complaints 
persisted. Examination by the ophthalmologist revealed decreased visual acuity in both eyes, 4/10 in the right eye 
(OD) and 5/10 in the left eye (OS), decreased color vision as demonstrated by a score of 1/13 in both eyes (OU) on 
Ishihara pseudoisochromatic plates, OS cataract, and dry age‑related macular degeneration (ARMD). Computerized 
static perimetry showed non‑specific diffuse alterations suggestive of either bilateral retinopathy or optic neuropathy. 
Full‑field electroretinography (ERG) disclosed moderate diffuse rod and cone dysfunction and multifocal ERG revealed 
central loss of function OU. Visual symptoms progressively improved over the next 2 months, but multifocal ERG did 
not. The patient was finally discharged home after a 5 week hospital stay.
Conclusion: This case is a reminder of a complication of digoxin treatment to be considered by any treating physi‑
cian. If digoxin is prescribed in a vulnerable patient, close monitoring is mandatory. In general, when facing a new 
health problem in a polymorbid patient, it is crucial to elicit a complete history, with all recent drug changes and 
detailed complaints, and to include a drug adverse reaction in the differential diagnosis.
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Background
Digitalis glycosides’ long history in medical practice has 
been beautifully explored by English pharmacologist Jeff 
K. Aronson some 20 years ago. His in-depth study, cen-
tered on the work by 18th century English physician and 
scientist William Withering, shows that their narrow 
therapeutic margin has been recognized and dealt with 
for several thousand years [1].
Digoxin is the main form of digitalis medically used in 
Switzerland today. It is extracted from the leaves of the 
plant Digitalis lanata. It combines with and reversibly 
inhibits the cell membrane Na+/K+-ATPase, induc-
ing an increase in intracellular calcium, intracellular 
sodium, and extracellular potassium. In the heart, this 
leads to an increase in myocardium’s strength of contrac-
tion and excitability, as well as to a decrease in conduc-
tion and depolarization velocity in the atrio-ventricular 
node. Current indications to digoxin are restricted to 
second line treatment for paroxystic or permanent atrial 
fibrillation (AF), second line treatment for symptomatic 
heart failure with rapid AF, or as a last resort for severe, 
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symptomatic systolic heart failure (left ventricular ejec-
tion fraction ≤40 %) [2, 3].
Pharmacological properties of digoxin are as follows: 
bioavailability 70–80  %, distribution volume 5–7  l/kg, 
poor protein binding (25  %), time to peak concentra-
tion 1  h, time to peak effect 6  h after oral administra-
tion. Metabolism is negligible and elimination essentially 
occurs through glomerular filtration, with a small con-
tribution of tubular secretion involving P-glycoprotein. 
Digoxin has a long half-life (40  h; 100  h and beyond in 
kidney disease).
Usual maintenance dosing is 0.25  mg qd. In kidney 
disease, empirical dose reductions are proposed accord-
ingly, for example 50–75 % of usual dosing for a creati-
nine clearance (CrCl) of 50–100 ml/min according to the 
Cockroft-Gault formula, 30–50  % of usual dosing for a 
CrCl of 20–50 ml/min, and 20–30 % of usual dosing for 
a CrCl <20 ml/min. These are general guidelines only, as 
plasma creatinine is a poor indicator of kidney function 
in very ill or sarcopenic elderly people. Drug monitoring 
and scrupulous follow-up are mandatory in such cases.
Digoxin toxicity predominantly manifests as digestive 
or neurological symptoms. Cardiac symptoms are less 
frequent but are related to the seriousness of digoxin 
poisoning, the overall rate of mortality being estimated 
at 25  %. Out of range potassium, calcium or magne-
sium levels can modulate digoxin action. Neurologic 
symptoms are multifold, including headache, confusion, 
somnolence, fatigue, restlessness and visual symptoms. 
Elderly patients are more susceptible to digoxin toxic-
ity for a variety of reasons including kidney disease, a 
decrease in muscular mass, frequent polypharmacy (diu-
retics and amiodarone being the most frequent at-risk 
co-medication), and poor adherence due to sensory and 
cognitive impairment [4].
The earliest report of digitalis-associated ocular toxic-
ity we could easily access was published in 1925 in the 
Boston Medical and Surgery Journal, ancestor of the 
New England Journal of Medicine [5]. According to the 
authors: “Sensory disturbances associated with an over-
dose of digitalis […] are met with rarely, and even then 
may easily be overlooked simply because their meaning 
is not clear.” They proceed with reporting the illness of 
a 55-year-old woman who, after 1 year of regularly tak-
ing digitalis, “developed an attack of failing vision. Eve-
rything appeared yellow before her eyes.” Later on, “She 
was unable clearly to distinguish objects and persons at 
a distance, and everything seemed to be bathed in a very 
intense glaring white light […]. The air seemed filled with 
yellow snow, and the grass appeared distinctly blue in 
color. The sky appeared green. At times she had double 
vision, […] at times she saw T shaped objects in the sky 
or any blank surface.” The authors conclude: “It may be 
that the condition of yellow vision is more common than 
we suppose and that more careful questioning of patients 
with toxic manifestations of digitalis will reveal this fact”.
As geriatricians, ophthalmologists, and clinical phar-
macologists, we recently cared for an elderly woman suf-
fering from several visual symptoms related to digoxin 
intoxication. We tell her story as a well documented case 
of digoxin ocular toxicity, as well as a reminder that the 
need for “careful questioning” still holds true in medical 
practice today.
Case presentation
A 91-year-old female patient, weight 56  kg, height 
151 cm, was admitted to the emergency room (ER) of a 
tertiary hospital complaining about dysphagia, vomiting 
and blurry vision. She was in altered general condition 
but hemodynamically stable; detailed physical examina-
tion was unremarkable. Electrocardiography showed 
paced rhythm, 60/min. She felt so ill she repeatedly said 
she’d have to enter a nursing home.
The patient lived alone at home. She got daily help 
from her daughter and the local home care services, and 
sometimes made mistakes while managing her medica-
tion. She suffered from multiple co morbidities, includ-
ing hypertension, hypercholesterolemia, type 2 diabetes, 
ischemic heart disease with heart failure, chronic kidney 
disease (creatinine clearance according to Cockroft-Gault 
formula, CrCl, 18 ml/min), gout, and indolent breast can-
cer. A pacemaker had been implanted 2 years earlier for 
permanent atrial fibrillation (AF) with insufficiently con-
trolled ventricular rate. She had benefited from right eye 
cataract surgery. She was under the regular care of a gen-
eral practitioner (GP), a nephrologist, a cardiologist, an 
ophthalmologist and an oncologist.
Her medication consisted of acenocoumarol qd (dosing 
according to International Normalized Ratio, targeted 
range 2.0–3.0), metoprolol 100 mg qd, lisinopril 5 mg qd, 
torasemide 20 mg qd, simvastatin 20 mg qd, anastrozole 
1 mg qd, ibandronate 150 mg monthly, lorazepam 0.5 mg 
qd, folate 5 mg qd, calcium 500 mg/cholecalciferol 400 IU 
bd, and zolpidem 5 mg qd as needed.
Digoxin, 0.25 mg qd, and diltiazem, 90 mg qd, had been 
started exactly 1 month earlier by her cardiologist for AF 
with rapid ventricular response. In a letter to the GP sent 
7 days after the patient was started on digoxin, the car-
diologist mentioned the need for measuring the digoxin 
level and adapting the dosing, without specifying a dead-
line. He also reported intending atrioventricular node 
ablation therapy 5 weeks later.
A detailed history given by the patient, her daughter, 
and the home care services revealed that on the 7th day 
after starting digoxin, the patient suffered a fall, which 
led her GP to stop diltiazem on the 8th day. On the 13th 
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day, she had “digestive symptoms” and difficulty eating. 
From the 18th day on, she complained of significant loss 
of vision in both eyes, seeing “everything in white”.
Five months previously, she had been routinely exam-
ined by her ophthalmologist. Visual acuity was 10/10 
difficult in both eyes, and fundus examination disclosed 
the presence of slight retinal pigment epithelium changes 
compatible with early dry age-related macular degen-
eration (ARMD). On the 21th day of digoxin therapy, 
an emergency consultation at the eye clinic revealed 
decreased visual acuity in both eyes (4/10 OD and 5/10 
OS), a mature cataract in the left eye and dry ARMD in 
both eyes. From then on, the patient lost 5 kg because of 
nausea and vomiting, and her vision remained severely 
impaired.
Her symptoms varied from day to day but included 
blurry vision (she couldn’t read a printed text anymore), 
snowy vision (everything appeared to be bathed in a 
white light), a tendency to collide with objects on her 
right side, dyschromatopsia (she was seeing blue or pur-
ple spots when she closed her eyes, vivid colors appeared 
to be faded), formed visual hallucinations of little human 
figures that did not frighten her appearing either upon 
awakening (hypnopompic) or shortly before falling asleep 
(hypnagogic), and feeling as if she was on a fishing boat 
when lying in bed (proprioceptive illusions).
Digoxin intoxication was suspected on admission 
1  month after its initiation, and confirmed when the 
serum level was measured to be 5.7  ng/ml [0.8–2.0].1 
Other relevant laboratory results were as follows (refer-
ence range in brackets): creatinine 183  µmol/l [44–80], 
sodium 144  mmol/l [135–145], potassium 4.0  mmol/l 
[3.5–4.6], calcium 2.41 mmol/l [2.10–2.50].
Digoxin was definitively stopped, and further lev-
els were as follows (all samples were taken at 6 am, day 
0  =  day of ER admission): Day 3: 4.0  ng/ml. Day 10: 
1.1 ng/ml. Day 18: not to be detected. On this basis, we 
estimated the half-life to be approximately 80–90  h in 
this patient at that time. Chest radiography, brain com-
puted tomography scan and oesogastric studies provided 
no contributive finding in explaining the symptoms.
After digoxin withdrawal, nausea and vomiting were 
first to disappear in the next few days. Her general condi-
tion then improved, the patient gained weight and ben-
efited from a hospital rehabilitation program.
On the 17th day after ER admission, a detailed oph-
thalmological examination was performed. Visual symp-
toms were persistent, including snowy and blurry vision, 
1 The last time the patient had taken digoxin could not be determined with 
certainty, but was supposed to have been approximately 48 h prior to blood 
sampling.
peripheral fixed photopsias and dyschromatopsia, all 
compatible with digoxin intoxication, as well as formed 
visual hallucinations occurring systematically when the 
patient fell asleep (hypnagogic visual hallucinations). 
Visual acuity was decreased in both eyes (4/10 OD with 
S−1.25, C−1.5 at 103° and 5/10 OS with S+1.25) and 
color vision testing with Ishihara pseudoisochromatic 
plates disclosed a severe red-green dyschromatopsia 
(only 1/13 plates correctly identified with either eye). 
Slit-lamp examination showed a pseudophakic OD and a 
mature corticonuclear OS cataract. Intraocular pressures 
were normal (12 mmHg OU). Funduscopy revealed nor-
mal optic nerve head with peripapillary atrophy OU, nor-
mal retinal vessels and bilateral minimal macular changes 
compatible with bilateral early dry ARMD. Computerised 
static perimetry (Octopus model 300) showed non-spe-
cific diffuse sensitivity loss consistent with bilateral dif-
fuse retinopathy. Compared to our normative data for 
the age group, full-field photopic and scotopic ERGs con-
firmed a moderate diffuse dysfunction more pronounced 
for cones than rods (photopic and scotopic b-wave ampli-
tude was decreased to 60  % of the lower normal values 
for the age). Qualitative interpretation of multifocal ERG 
disclosed a diffuse decrease of amplitude mostly in the 
central ten degrees.
The patient was finally discharged home 44 days after 
ER admission. She was still living at home 6 months after 
ER admission according to elicited follow-up. At that 
time, tests showed a subtle improvement of visual acu-
ity (6/10 OD and 5/10 OS), persistent severe red-green 
dyschromatopsia (1/13 on Ishihara test OU), and a slight 
non significant amplitude increase on the multifocal 
ERG. Unfortunately, she denied further ophthalmologic 
examinations beyond follow-up at 6 months.
Discussion and literature review
In this patient, the time course and characteristics of the 
clinical evolution, and the constellation of symptoms 
were attributed with high probability to digoxin intoxi-
cation, notably in view of the elevated drug level (score 
of 9/13 according to the Naranjo Adverse Drug Reaction 
Probability Scale [6]).
Many risk factors for these adverse drug reactions were 
present:
1. A drug with a narrow therapeutic margin was 
administered at standard dosing with insufficient 
pre-defined follow-up strategy to a particularly vul-
nerable patient because of advanced age, polymor-
bidity, polymedication with questionable adherence, 
and pre-existing advanced kidney disease as well as 
functional and ocular impairment. Specific interact-
ing drugs were diltiazem (which increases exposure 
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to digoxin through uncertain mechanisms, possibly 
by inhibiting P-glycoprotein) and torasemide and 
lisinopril (which aggravate renal failure and the risk 
of dehydration and electrolyte imbalance).
2. Many people were involved in the care of the patient, 
and her symptoms were, at least in the beginning, 
entirely non-specific. Loose communication between 
the cardiologist and the GP, dilution of responsi-
bilities and failure to rapidly identify and incrimi-
nate drugs as a plausible cause were all elements 
that could contribute to the delay in diagnosing this 
potentially life-threatening intoxication.
Further discussion will focus on neurologic symptoms, 
with particular emphasis on visual symptoms.
Although dysphagia was mentioned on admission, it is 
difficult to be positive it was really part of the clinical pic-
ture, because the patient then stopped complaining about 
it and later even denied having ever suffered from it. Two 
case reports describe dysphagia in digoxin intoxication in 
elderly women, but the clinical picture was more clear-
cut [7, 8].
Proprioceptive illusions are described in another case 
report as “[the patient complained that] the room was 
hilly and that the bed was continuously sliding downhill” 
[9].
Disturbances of vision during digoxin treatment are 
less common than cardiac or other non cardiac symp-
toms, but are considered by some authors to be more 
specific. In this patient, cardiac symptoms are likely to 
have been concealed by the implanted pacemaker. The 
spectrum of visual complaints include decreased visual 
acuity, central scotomas or visual field reduction, glare, 
photopsia most pronounced in daylight, photophobia, 
blurry or snowy vision, visual hallucinations, diplo-
pia, and dyschromatopsia including xanthopsia (yellow 
vision), cyanopsia (blue vision) and chloropsia (green 
vision). Dyschromatopsia can be asymptomatic and 
revealed only by formal testing; several studies report a 
positive correlation between the total error score at test-
ing and serum digoxin level. A more recent study in 30 
elderly hospitalized patients receiving digoxin mainte-
nance therapy compared to controls did not confirm this 
correlation, but the authors reported a high incidence of 
impaired color vision at serum digoxin levels considered 
therapeutic as well as supra-therapeutic, speaking for 
limited value of formal color vision testing for the detec-
tion of toxicity in the aged [10].
The mechanism underlying ocular symptoms is pre-
sumed to be related to Na+ K+ATPase inhibition but 
remains speculative [9, 11]. Ophthalmologic tests con-
sidered most useful to support a diagnosis of digoxin 
intoxication are photopic and scotopic ERG seeking 
for b-wave delayed implicit time and decreased b-wave 
amplitude.
In our patient, visual symptoms improved after stop-
ping digoxin, yet some persisted for several weeks, long 
after drug levels became undetectable, and others had 
not resolved after 6  months. We offer several possible 
explanations for this. First, digoxin elimination was slow 
because of its high volume of distribution and prolonged 
half-life in this patient. It could also be hypothesized that 
serum digoxin levels more poorly correlate with certain 
specific pharmacodynamic effects (for example, dura-
tion of the effect may possibly vary according to different 
clearances from deep tissue compartments or variability 
in inhibition by digoxin of different Na /K+-ATPase iso-
forms in different body tissues). Second, the patient may 
have been more worried about and inclined to express 
ocular symptoms because of the attention given to them 
by clinicians. Third, the underlying eye diseases may 
themselves have evolved over the time. Eventually, the 
patient refused to continue ophthalmologic follow-up 
beyond 6 months hereby escaping longer monitoring.
Arbitrarily starting our literature review in the seven-
ties, we found a total of 15 references to case reports of 
impaired vision during digoxin maintenance therapy or 
in  situations of chronic supratherapeutic digoxin lev-
els. These publications describe a total of 52 patients 
(Table  1), with only five cases described in more recent 
years (since 2000). Quality of documentation and degree 
of detail are highly unequal among studies, which does 
not allow for a quantitative analysis. As a whole, most 
patients are aged (>65-year-old), with only one patient 
being under 40. Ocular symptoms are numerous. Digoxin 
levels also vary greatly, but many are in the suprathera-
peutic or more clearly toxic range. Finally, full resolution 
is almost always witnessed over the course of 1–2 weeks, 
but here again follow-up is heterogeneous and often of 
short duration.
Conclusion
We describe a case of digoxin intoxication in a patient 
at highest risk for this adverse outcome due to differ-
ent endogenous and exogenous factors: advanced age, 
polymorbidity including severe chronic kidney disease, 
preexistent ocular disease, insufficient communica-
tion among carers and failure to include a drug-induced 
adverse reaction in the differential diagnosis. It is unique 
by its extensive description of ophthalmologic find-
ings, over a 6 month follow-up. Above all, this case is a 
reminder of a complication of digoxin treatment to be 
considered by any treating physician. If digoxin is pre-
scribed in a vulnerable patient, close monitoring is man-
datory. In general, when facing a new health problem 
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in a polymorbid patient, it is crucial to elicit a complete 
history, with all recent drug changes and detailed com-
plaints, and to include a drug adverse reaction in the dif-
ferential diagnosis.
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